سعر ناوزيليكس 50مجم/2مل حقن عضل/وريد 3 أمبولات 2026

Nausilex 50 mg/2 ml solution for injection, 3 ampoules (Minapharm, Egypt): each ampoule contains alizapride hydrochloride 55.8 mg equal to 50 mg alizapride; for IM/IV use. Egyptian manufacturer datasheet/package insert (2014) opened.

• Nausea and vomiting associated with anticancer therapy (Nausilex injection — Egyptian insert).Population: AdultsMinapharm Egypt

• Extrapyramidal symptoms, drowsiness, vertigo, headache, insomnia; GI effects; endocrine effects (hyperprolactinaemia, amenorrhea, galactorrhea, gynaecomastia); allergic reactions; vasomotor flushes after IV; orthostatic hypotension at high doses.Egyptian label · Minapharm Egypt

• Hypersensitivity to alizapride or excipients; prior tardive dyskinesia to neuroleptics; pheochromocytoma; combination with levodopa; pregnancy and lactation.Egyptian label · Minapharm Egypt

• Prefer treatment duration ≤7 days; reduce dose in severe renal failure; avoid alcohol; caution in epilepsy; discontinue if neuroleptic malignant syndrome suspected.Egyptian label · Minapharm Egypt

• LevodopaMajorReciprocal antagonism between levodopa and neuroleptic medications.Minapharm Egypt
• AlcoholModerateEnhances sedative effect of alizapride.Minapharm Egypt
• CNS sedativesModerateSedative effects of CNS depressants and alizapride are enhanced.Minapharm Egypt

• Egyptian insert: should not be prescribed during pregnancy; not recommended in lactation (milk excretion unknown).Egyptian label · Minapharm Egypt
• Not recommended during lactation.Egyptian label · Minapharm Egypt

• Alizapride: Raises the sensitivity threshold of the vomiting centre in the brainstem (Egyptian insert).

Ampoules: store at temperature not exceeding 30°C.